Abstract #3743: SGI-1776: A novel PIM kinase inhibitor with potent preclinical activity against Acute Myeloid Leukemia (AML)
Ronan Swords(University of Miami), Jennifer S. Carew(University of Arizona), Ernest Medina(The University of Texas at San Antonio Health Science Center), David J. Bearss(Unknown), Joi Ninomoto, Francis J. Giles(National University of Ireland), Steffan T. Nawrocki(University of Arizona), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Gregory Berk, Kevin R. Kelly(Keck Hospital of USC)
Cancer Research
May 1, 2009
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782